Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase NA 1Phase 3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Carcinoma, Non-Small-Cell Lung 84Breast Neoplasms 61Prostatic Neoplasms 43Lung Neoplasms 35Multiple Myeloma 34Neoplasms 27Leukemia, Lymphocytic, Chronic, B-Cell 22Colorectal Neoplasms 22Parkinson Disease 4, Autosomal Dominant Lewy Body 21Neoplasm Metastasis 19Ovarian Neoplasms 18Carcinoma, Renal Cell 17Urinary Bladder Neoplasms 13Small Cell Lung Carcinoma 13Pancreatic Neoplasms 13Leukemia, Myeloid, Acute 12Endometrial Neoplasms 12Squamous Cell Carcinoma of Head and Neck 11Recurrence 11Nasopharyngeal Carcinoma 11Myasthenia Gravis 11Triple Negative Breast Neoplasms 10Stomach Neoplasms 10Non-Muscle Invasive Bladder Neoplasms 10Lymphoma, Non-Hodgkin 9Lymphoma, Follicular 9Fallopian Tube Neoplasms 9Melanoma 8Colonic Neoplasms 8Lymphoma, Large B-Cell, Diffuse 7

Interventions

pembrolizumab 1X-Rays 1Specimen Handling 1Doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Histiocytoma, Malignant Fibrous × 30 days × Clear all
NCT06422806 2026-05-29

Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

National Cancer Institute (NCI)

Phase 3 Recruiting
365 enrolled
Sarcoma

Liposarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡